Literature DB >> 18096510

Determining prognosis after spinal cord injury.

Xoan Miguens Vazquez1, Maria Sol Rodriguez, Jose Manuel Suarez Peñaranda, Luis Concheiro, Jose Ignacio Muñoz Barus.   

Abstract

INTRODUCTION: Disability following traumatic spine injury often requires assessment for judicial reasons.
OBJECTIVE: To determine the optimum time to carry out a medico-legal evaluation.
METHODS: Retrospective study (1995-2000) of patients with traumatic spine injury with a follow-up of five years. The American Spinal Injury Association (ASIA) scale was used to determine level and extent of the injury. Statistical analysis by SPSS 11.0. RESULTS AND DISCUSSION: 173 injuries were analyzed (39.3% ASIA A; 15.6% ASIA B; 29.47% ASIA C; 15.6% ASIA D). Neurological improvement was detected in 35.83%, more frequently in incomplete injuries. ASIA A injuries remained mainly complete from admission to discharge and in no case reached functional levels. Only a third of ASIA B patients showed improvement, of whom 33.3% were functional. Improvement in ASIA C patients was 76.4%, these and all ASIA D patients were functional on discharge. The condition a year after the injury remained unchanged in all cases, regardless of the extent of injury. Patients who showed improvement did so early on, mainly during hospitalization.
CONCLUSIONS: The optimum time for evaluation of spinal cord injury for medicolegal purposes is at one year after the injury. In cases of complete injury, evaluation can be carried out on discharge with no need to wait for one year.

Entities:  

Mesh:

Year:  2007        PMID: 18096510     DOI: 10.1016/j.jflm.2007.06.003

Source DB:  PubMed          Journal:  J Forensic Leg Med        ISSN: 1752-928X            Impact factor:   1.614


  8 in total

1.  Classifications In Brief: American Spinal Injury Association (ASIA) Impairment Scale.

Authors:  Timothy T Roberts; Garrett R Leonard; Daniel J Cepela
Journal:  Clin Orthop Relat Res       Date:  2016-11-04       Impact factor: 4.176

Review 2.  Clinical predictors of recovery after blunt spinal cord trauma: systematic review.

Authors:  Amro F Al-Habib; Najmedden Attabib; Jonathon Ball; Sohail Bajammal; Steve Casha; R John Hurlbert
Journal:  J Neurotrauma       Date:  2010-04-08       Impact factor: 5.269

3.  Extensive neurological recovery from a complete spinal cord injury: a case report and hypothesis on the role of cortical plasticity.

Authors:  Ann S Choe; Visar Belegu; Shoko Yoshida; Suresh Joel; Cristina L Sadowsky; Seth A Smith; Peter C M van Zijl; James J Pekar; John W McDonald
Journal:  Front Hum Neurosci       Date:  2013-06-25       Impact factor: 3.169

4.  Spinal Cord Injury: A Review of Current Management Considerations and Emerging Treatments.

Authors:  Michelot Michel; Matthew Goldman; Rodeania Peart; Melanie Martinez; Ramya Reddy; Brandon Lucke-Wold
Journal:  J Neurol Sci Res       Date:  2021-12-10

5.  Validation and application of the International Classification of Functioning core set for spinal cord injury in the Turkish patients.

Authors:  Hilmi Umut Tatlı; Belma Füsun Köseoğlu; Didem Sezgin Özcan; Sinem Koçer Akselim; Asuman Doğan
Journal:  Turk J Phys Med Rehabil       Date:  2019-01-30

6.  Factors affecting outcome of acute cervical spine injury: A prospective study.

Authors:  Bhavanam Hanuma Srinivas; Alugolu Rajesh; A K Purohit
Journal:  Asian J Neurosurg       Date:  2017 Jul-Sep

7.  Efficacy, safety and prognosis of treating neurological deficits caused by spinal tuberculosis within 4 weeks' standard anti-tuberculosis treatment: A single medical center's experience.

Authors:  Chen-Guang Jia; Jian-Guo Gao; Feng-Sheng Liu; Zhuo Li; Zhao-Liang Dong; Li-Ming Yao; Lian-Bo Wang; Xiao-Wei Yao
Journal:  Exp Ther Med       Date:  2019-11-27       Impact factor: 2.447

8.  A 50 kdyne contusion spinal cord injury with or without the drug SS-31 was not associated with major changes in muscle mass or gene expression 14 d after injury in young male mice.

Authors:  Zachary A Graham; Jennifer J DeBerry; Christopher P Cardozo; Marcas M Bamman
Journal:  Physiol Rep       Date:  2021-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.